Clinical Trial

DORAvirine Versus DOlutegravir Based Antiretroviral Regimens in Treatment-naïve People Living With HIV-1 Infection

Study acronym: ELDORADO
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Phase III trial evaluating doravirine as an alternative to dolutegravir in treatment naïve people living with HIV-1 infection.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-11 -> 2028-01 2026-07-28
minor Completion pushed: 2027-11 -> 2029-01 2026-07-28
Trial Details
NCT Number NCT06203132
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: MSD France, European and Developing Countries Clinical Trials Partnership (EDCTP)
Conditions HIV-1-infection
Enrollment 610 participants
Start Date 2025-01-27
Primary Completion 2028-01 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-27